PRL and cancer: Although anti-PRL antibodies have been generated and proved valuable tools to treat PRL over-expressing cancers in preclinical settings [100,101,102], their mechanism of action is not preventing PRL trimers to form but rather mounting an efficient and specific antibody-mediated immune response against this intracellular oncotarget.